'For
the quarter ending March 2024, consolidated net sales (including other operating income) of Dr Reddys Laboratories has increased 12.65% to Rs 7113.8 crore compared to quarter ended March 2023. Sales of Pharmaceutical Services segment has gone up 12.76% to Rs 1,172.50 crore (accounting for 15.75% of total sales). Sales of Global Generics segment has gone up 12.88% to Rs 6,128.90 crore (accounting for 82.33% of total sales). Sales of Others segment has gone up 53.71% to Rs 143.10 crore (accounting for 1.92% of total sales). Inter-segment sales rose Rs 247.40 crore to Rs 330.70 crore. Profit before interest, tax and other unallocable items (PBIT) has jumped 15.23% to Rs 4,148.80 crore. PBIT of Pharmaceutical Services segment rose 19.24% to Rs 234.90 crore (accounting for 5.66% of total PBIT). PBIT of Global Generics segment rose 13.25% to Rs 3,793.70 crore (accounting for 91.44% of total PBIT).&nb...
Pleaselogin & subscribe to view the full report.
More Reports
-
(17-Aug-2024)
AIA Engineering
Net down 5% on lower sales
-
(17-Aug-2024)
Voltas
Net jump 159% on good operating show
-
(17-Aug-2024)
ABB India
Net up 50% on good operating show
-
(17-Aug-2024)
NHPC
Sales down 2%, net down 1%
|
|